Peter Oppelt, MD

Medical Oncologist

Peter Oppelt

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Clinical Expertise

  • Head and Neck

Primary Academic Title

Associate Professor of Medicine, Division of Medical Oncology, WashU Medicine

Board Certification

  • 2011: American Board of Internal Medicine
  • 2015: American Board of Internal Medicine - Medical Oncology
  • 2015: American Board of Internal Medicine - Hematology

Training

  • 2008 - 2011: Resident, Internal Medicine, University Hospitals Case Medical Center, Cleveland, OH
  • 2011 - 2012: Chief Medical Resident, Internal medicine, University Hospitals Case Medical Center, Cleveland, OH
  • 2012 - 2015: Fellow, Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH

Education

  • 2008: MD, University of Missouri, Columbia, MO

Research & Selected Publications

Research Publications

Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Authors:

Adkins D, Ley JC, Auberle C, one or more additional authors omitted Oppelt P

Journal & Year:

Cancer Med | 2026

Mitomycin-C for HPV-Positive and HPV-Negative Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial
Authors:

Oppelt P, Ley J, Auberle C, one or more additional authors omitted Adkins D

Journal & Year:

Cancers (Basel) | 2025

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Authors:

Grierson PM, Wolf C, Suresh R, one or more additional authors omitted Oppelt P, one or more additional authors omitted Lim KH

Journal & Year:

Clin Cancer Res | 2025

Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus-Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma…
Authors:

Oppelt PJ, Ley JC, Puram SV, one or more additional authors omitted Adkins DR

Journal & Year:

JCO Precis Oncol | 2025

Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial
Authors:

Oppelt PJ, Puram SV, Liu J, Ley JC , Adkins D

Journal & Year:

Cancers (Basel) | 2025

Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial
Authors:

Adkins D, Ley JC, Liu J, Oppelt P

Journal & Year:

JCO Oncol Adv | 2025

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial
Authors:

Dzienis M, Cundom J, Fuentes CS, one or more additional authors omitted Oppelt P, one or more additional authors omitted de Castro G

Journal & Year:

J Clin Oncol | 2024

Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial
Authors:

Adkins D, Ley JC, Liu J, Oppelt P

Journal & Year:

Lancet Oncol | 2024